{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:42:09Z","timestamp":1792258929569,"version":"4.4.0"},"reference-count":42,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Review the pharmacology, efficacy, and safety of lecanemab, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody, for the treatment of early Alzheimer\u2019s disease (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>Comprehensive search of Embase, PubMed, International Pharmaceutical Abstracts, Cochrane CENTRAL, Scopus, Web of Science, and Google Scholar were conducted from inception through December 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Phase I-III clinical trials, systematic reviews, and meta-analyses evaluating lecanemab pharmacology, pharmacokinetics, efficacy, and safety were included. Product labeling was reviewed to supplement clinical data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>\n                      In the phase III Clarity AD trial, patients were randomized 1:1 to lecanemab 10 mg\/kg every 2\u2009weeks or placebo. The primary endpoint was change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) score at 18 months. Lecanemab demonstrated a mean change of 1.21 versus 1.66 with placebo (difference, \u22120.45; 95% CI, \u22120.67 to \u22120.23;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001). Secondary endpoint, amyloid burden via positron emission tomography (PET) scans (\n                      <jats:italic toggle=\"yes\">\n                        <jats:underline>n<\/jats:underline>\n                      <\/jats:italic>\n                      \u2009=\u2009698) showed \u221255.48 centiloids with lecanemab versus 3.64 with placebo (difference \u221259.12 centiloids; 95% CI, \u221262.64 to \u221255.6;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001). Additional endpoints included changes in ADAS-cog 14, ADCOMS, and ADCS-MCI-ADL scores favoring lecanemab over placebo. Lecanemab was well tolerated; infusion site reactions occurred in 26.4%. Amyloid-related imaging abnormalities (ARIA-E) occurred in 12.6% of participants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Compared to placebo, lecanemab demonstrated statistically significant slowing of cognitive decline on CDR-SB and secondary endpoints, including amyloid burden reduction. However, its clinical benefit must be weighed against ARIA risk and substantial financial burden. Current evidence supports its use in carefully selected patients with early AD under close supervision.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/87551225261492568","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:00:18Z","timestamp":1792040418000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Lecanemab\u2014Monoclonal Antibodies for the Treatment of Early Alzheimer\u2019s Disease"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-6537","authenticated-orcid":false,"given":"Jasmine","family":"Cutler","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapeutics and Clinical Research, University of South Florida Health Taneja College of Pharmacy, Tampa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7116-9847","authenticated-orcid":false,"given":"Bao Anh","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Clinical Research, University of South Florida Health Taneja College of Pharmacy, Tampa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystal","family":"Bullers","sequence":"additional","affiliation":[{"name":"University of South Florida Health Libraries Emerging Technologies, Tampa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Clinical Research, University of South Florida Health Taneja College of Pharmacy, Tampa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13016"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211050405"},{"key":"e_1_3_2_5_2","unstructured":"Aduhelm (aducanumab-avwa). Package insert. Biogen Inc; 2023."},{"issue":"4","key":"e_1_3_2_6_2","first-page":"353","article-title":"Why physicians should not prescribe aducanumab for Alzheimer disease","volume":"105","author":"Ebell MH","year":"2022","unstructured":"Ebell MH, Barry HC. Why physicians should not prescribe aducanumab for Alzheimer disease. Am Fam Physician. 2022;105(4):353-354.","journal-title":"Am Fam Physician"},{"key":"e_1_3_2_7_2","unstructured":"Alzheimer\u2019s Association. Aducanumab discontinued as an Alzheimer\u2019s treatment. Accessed May 21 2026. https:\/\/www.alz.org\/alzheimers-dementia\/treatments\/aducanumab"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0181-2"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-00995-9"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_2_12_2","unstructured":"Leqembi (lecanemab). Package insert. Eisai Inc; 2026."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2178414"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00373-5"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.082852"},{"key":"e_1_3_2_16_2","unstructured":"Biogen. LEQEMBI IQLIK\u00ae (lecanemab-irmb) autoinjector for initiation of therapy now available in the U.S. for early Alzheimer\u2019s disease 2026. Accessed September 1 2026. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/leqembi-iqlikr-lecanemab-irmb-autoinjector-initiation-therapy"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12377"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18020530"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01441-8"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70905"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.123"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-026-00677-4"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.092094"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz70861_108905"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.70404"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-025-01253-x"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-023-00976-6"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2016.02.004"},{"key":"e_1_3_2_29_2","unstructured":"National Council on Aging. Alzheimer\u2019s medication Leqembi is covered by Medicare\u2014but access and effectiveness questions remain. Accessed June 25 2024. https:\/\/www.ncoa.org\/article\/alzheimers-medication-leqembi-now-covered-by-medicare-but-access-and-effectiveness-questions-remain"},{"key":"e_1_3_2_30_2","unstructured":"Centers for Medicare and Medicaid Services. Alzheimer\u2019s CED registry resources. CMS.gov. Accessed May 29 2024. https:\/\/qualitynet.cms.gov\/alzheimers-ced-registry\/resources"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.1232"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209218"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00790-2"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26819"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70062"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100068"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102193"},{"key":"e_1_3_2_38_2","unstructured":"ClinicalTrials.gov. A study of E2814 with concurrent lecanemab treatment in participants with early Alzheimer\u2019s disease 2026. Accessed September 1 2026. https:\/\/clinicaltrials.gov\/study\/NCT06602258"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0065"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100266"},{"key":"e_1_3_2_41_2","unstructured":"Kisunla (donanemab-azbt). Package insert. Eli Lilly and Company; 2024."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161"}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225261492568","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/87551225261492568","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225261492568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:51:42Z","timestamp":1792255902000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/87551225261492568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":42,"alternative-id":["10.1177\/87551225261492568"],"URL":"https:\/\/doi.org\/10.1177\/87551225261492568","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"article-number":"87551225261492568"}}